Also
- Share via
Novartis said its anti-cancer drug Gleevec is receiving a priority review from the Food and Drug Administration for use by a wider range of sufferers.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
